FDA Issues Final Guidance on Prescription Drug Apps and Software

On October 20, 2026, FDA's Center for Drug Evaluation and Research released final guidance establishing a regulatory framework for companion apps and software distributed alongside prescription drugs. The guidance addresses three core questions: when app content constitutes FDA-required labeling versus promotional labeling, when an app must be referenced in a drug's official prescribing information, and what submission obligations apply when companies distribute app content to users. The guidance establishes two categories of companion software subject to different labeling treatment. Apps connected to a medical device, such as software paired with an asthma inhaler, generally must be described on the drug's official prescribing label given the software's central role in how the medicine is administered. Standalone apps, including symptom trackers, dose reminders, and health coaching tools, must appear on the prescribing label only if the company demonstrates the app is essential for safe and effective use or shows a meaningful clinical benefit. For content displayed to users within a companion app, the guidance states that such content will in most cases be treated as promotional material, consistent with FDA's existing framework for drug advertising. This classification carries submission and accuracy obligations applicable to other forms of drug promotion. The guidance is described as aligning regulatory approach across FDA's drug and device centers to provide a consistent pathway for digital health developers. FDA characterized the guidance as risk-proportionate oversight intended to reduce regulatory uncertainty for drug companies and their technology partners while preserving safety and effectiveness standards.